Asisat Ope
Family Medicine · Sugar Land, TXNPI 1992186928
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (42.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Modernatx, Inc. at 55.0% of the total. Reporting peaked in 2024 at $3,714 and has fallen 99.5% since, to $18 in 2025.
Across 87 payments — averaging $56.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$3K
- Pfizer$1K
- Novo Nordisk$198
- AbbVie$142
- Merck$83
- Antares Pharma, Inc.$53
- plus $572 from 18 others
Across 285 payments — averaging $7641.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.6M
- Seqirus USA Inc$341K
- Orasure Technologies Inc.$127K
- GSK$112K
- Pfizer$5K
What the payments were for
- Consulting fees$1,00021%
- Travel & lodging$2,07443%
- Food & beverage$1,79937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 16 | $2,680 |
| Pfizer | 8 | $1,146 |
| Novo Nordisk | 13 | $198 |
| AbbVie(2 entities) | 7 | $142 |
| Merck | 6 | $83 |
| Antares Pharma, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Amgen | 3 | $46 |
| AstraZeneca | 3 | $46 |
| Johnson & Johnson | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Optinose US, Inc. | 2 | $42 |
| Sanofi Pasteur Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $23 |
| GSK | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Eisai Inc. | 1 | $15 |
How this compares
$4,873 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sugar Land
- Anne Marie Ponce de LeonSugar Land$109K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.